Autism - Pipeline Review, H1 2020

January 2020 | 177 pages | ID: A5DD2D043B9EN
Global Markets Direct

Abstracts

Autism - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2020, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 20, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Autism - Overview
Autism - Therapeutics Development
Autism - Therapeutics Assessment
Autism - Companies Involved in Therapeutics Development
Autism - Drug Profiles
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Autism, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Autism - Pipeline by 4D Pharma Plc, H1 2020
Autism - Pipeline by AgeneBio Inc, H1 2020
Autism - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
Autism - Pipeline by APeT Holding BV, H1 2020
Autism - Pipeline by AsiaBiome, H1 2020
Autism - Dormant Projects, H1 2020
Autism - Dormant Projects, H1 2020 (Contd..1), H1 2020
Autism - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Autism, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
APeT Holding BV
AsiaBiome
Blackthorn Therapeutics Inc
BrainStorm Cell Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
Cox Biosciences LLC
Curemark LLC
Cytocom Inc
Epigen Biosciences Inc
F. Hoffmann-La Roche Ltd
GW Pharmaceuticals Plc
Immuron Ltd
Insys Therapeutics Inc
Intra-Cellular Therapies Inc
Johnson & Johnson
Neurochlore
Omeros Corp
OptiNose US Inc
Ovensa Inc
Panorama Research Inc
Park Active Molecules
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
RogCon Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Scioto Biosciences Inc
Sengenics International Pte Ltd
Sosei Heptares
Stem Cell Medicine Ltd
Sumitomo Dainippon Pharma Co Ltd
Zelira Therapeutics Ltd